Testing a drug for Alzheimer's-related agitation
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed diagnosis of Alzheimer's disease (through a brain scan or spinal tap).
- Have a history of agitation that started at least 2 weeks ago and is linked to Alzheimer's.
- Score 24 or less on a memory test called the Mini-Mental State Exam (MMSE).
- Have a caregiver who can help at least 8 hours a week and attend all study visits.
- Not have agitation caused by other conditions, prior bipolar/schizophrenia, or certain medical issues like bladder or eye problems.
- Not be taking certain psychiatric drugs, or be on a stable dose of allowed antidepressants for at least 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.